Unità dipartimentale linfomi IRCCS FONDAZIONE S. RAFFAELE DEL MONTE TABOR DI MILANO
Welcome,         Profile    Billing    Logout  
 15 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ferreri, Andrés JM
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
IELSG39, NCT01820910 / 2012-005702-22: Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

Active, not recruiting
2
34
Europe
Doxycycline
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma of Ocular Adnexal
05/16
09/25
NCT02329080: New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Completed
2
76
Europe, RoW
Methotrexate, Rituximab, Cytarabine, Thiotepa, liposomial cytarabine, Etoposide, Ifosfamide, Carmustine, whole brain radiotherapy
International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B-cell Lymphoma
08/19
03/24
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
12/24
12/24
FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting
2
28
Europe
Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
Plasmablastic Lymphoma
01/25
01/25
MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/27
06/27
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
ReWIPretro, NCT05782374: Real World Data on Ibrutinib Use in PCNSL Rel/Ref

Recruiting
N/A
36
Europe
Ibrutinib
IRCCS San Raffaele
PCNSL
01/23
08/23
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
N/A
350
Europe
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma
12/25
12/25
DOROTHEA, NCT05036564: Diagnosis; Objective RespOnse; THErApy

Recruiting
N/A
70
Europe
Lumbar puncture
IRCCS San Raffaele, Teresa Calimeri, Sara Steffanoni
Primary CNS Lymphoma
07/23
04/24
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT06024694: Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Recruiting
N/A
45
Europe
IRCCS San Raffaele
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
06/24
06/24
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26

Download Options